ERAS
ErascaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary-source evidence is not purely negative: the April 27 8-K reported dose-dependent PK, broad ctDNA reductions, strong early unconfirmed response rates in NSCLC and PDAC, selected 24 mg and 32 mg as go-forward monotherapy RDEs, and showed early combinability signals, while the 10-K said cash plus January 2026 financing proceeds less the Joyo payment should fund operations into the second half of 2028 [#8-K-2026-04-27] [#10-K-2026-03-12].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
A treatment-related pneumonitis event progressed to Grade 5 after supportive-care withdrawal, creating a real safety overhang around ERAS-0015 [#8-K-2026-04-27].
Momentum
28
Value
41
Sentiment
13
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $13.00 · Bear $5.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $11.50
Why
Momentum28 · Δ7d +23.0
Value41 · Δ7d +0.1
Sentiment13 · Δ7d -12.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
28
34% active weight
Current posture
7d trendImproving
Δ7d
+23.0
Δ21d
-0.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
13
33% active weight
Current posture
7d trendSoftening
Δ7d
-12.3
Δ21d
-14.4
Why this grade
Composite grade F. Momentum 28.0 / Value 41.1 / Sentiment 12.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$4.19B
Beta
1.15
Shares Out
283.71M
P/E (TTM) · Derived
-21.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-42.54
Rev YoY
-
EPS YoY
+2.3%
Gross Margin
-
Op Margin
-
Net Debt
-$298.31M
Current Ratio
10.45
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology